<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04582877</url>
  </required_header>
  <id_info>
    <org_study_id>WXYL-LC-2018001</org_study_id>
    <nct_id>NCT04582877</nct_id>
  </id_info>
  <brief_title>Pressure Guidewire System Multi-center, Prospective, Self-Control, Clinical Trial</brief_title>
  <official_title>Pressure Guidewire System Multi-center, Prospective, Self-Control, Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zurich Medical Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zurich Medical Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants with intermediate-grade coronary stenosis undergo measurement of fractional flow&#xD;
      reserve using the test article (Zurich Pressure Guidewire System) and predicate article&#xD;
      (Abbott PressureWire System). Both articles are used within the same participant and the FFR&#xD;
      values are statistically compared with each other.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compared FFR Measurement Between Test Article and Predicate Article</measure>
    <time_frame>Acute</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>FFR Measurement in Intermediate-Grade Coronary Stenosis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants with intermediate-grade coronary stenosis undergo measurement of fractional flow reserve using the test article (Zurich Pressure Guidewire System) and predicate article (Abbott PressureWire System).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FFR measurement</intervention_name>
    <description>FFR is measured sequentially with the test article and the predicate device.</description>
    <arm_group_label>FFR Measurement in Intermediate-Grade Coronary Stenosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 to 75 years old, gender-unrestricted, non-pregnant female;&#xD;
&#xD;
          -  Understand and be willing to sign an informed consent form;&#xD;
&#xD;
          -  Diagnosed with coronary heart disease;&#xD;
&#xD;
          -  Intrusive ICA and FFR measurement are needed;&#xD;
&#xD;
          -  Visual coronary angiography showed at least one moderate stenosis lesion (diameter&#xD;
             stenosis of 30% - 70%) on the coronary artery with diameter â‰¥ 2.5mm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who do not understand or are unwilling to sign an informed consent form;&#xD;
&#xD;
          -  Has a history of myocardial infarction;&#xD;
&#xD;
          -  Patient with other serious diseases are not suitable for clinical trials, such as a&#xD;
             complex congenital heart disease history, severe heart failure(NYHA cardiac function&#xD;
             level IV), long QT syndrome, severe hypertension, Severe asthma, severe chronic&#xD;
             obstructive pulmonary disease, liver and kidney dysfunction and other serious&#xD;
             infections and critical illnesses;&#xD;
&#xD;
          -  Coronary intervention surgery contraindications;&#xD;
&#xD;
          -  Patient with ATP contraindications (ATP contraindications: sinus syndrome, sinus&#xD;
             insufficiency and the elderly with cautious use or no use);&#xD;
&#xD;
          -  The clinical manifestations of patients show acute instability, including acute chest&#xD;
             pain (sudden appearance), cardiogenic shock, unstable blood pressure (systolic&#xD;
             pressure less than 90mmHg), severe congestive heart failure or acute pulmonary edema;&#xD;
&#xD;
          -  The angiography shown or suspect of thrombosis;&#xD;
&#xD;
          -  The angiography shown or suspect of dissection;&#xD;
&#xD;
          -  Left main coronary artery disease, target blood vessels with severe curvature or&#xD;
             calcification lesions, total occlusion;&#xD;
&#xD;
          -  There are any other factors that the investigator considers unsuitable for inclusion&#xD;
             or completion of this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Charles Chan</last_name>
    <phone>651-571-0020</phone>
    <phone_ext>103</phone_ext>
    <email>cchan@zurichmed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amber Daly</last_name>
    <phone>651-571-0020</phone>
    <phone_ext>118</phone_ext>
    <email>adaly@zurichmed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 17, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2020</study_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 7, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT04582877/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

